Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Bill.com Holdings Inc (BILL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Bill.com Holdings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Bill.com Holdings Inc trades at $41.2 (market cap $4.12B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 9.7× Bill.com Holdings Inc's market cap, and Bill.com Holdings Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | BILL | |
|---|---|---|
Market Cap | $39.89B | $4.12B |
Sector | Health | Technology |
52-Week High | $491.22 | $56.32 |
52-Week Low | $278.09 | $31.96 |
Enterprise Value | $38.15B | $3.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BILL Holdings trades at $41.36, up 2.07% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains a bullish technical outlook with support at $39 and resistance at $42. Revenue growth accelerated to $1.46 billion in 2025, though net margins remain thin at 0.01%. Recent leadership changes and a $1 billion buyback program signal confidence in future growth.
Outlook remains positive with 56% analyst buy ratings and a $48 consensus target suggesting 16% upside. Key risks include high valuation (P/E 214), competitive pressures in SMB software, and sensitivity to interest rate changes. The company's transition to profitability and AI integration present opportunities if execution continues improving.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Bill.com Holdings Inc
Bill.com Holdings Inc is a provider of cloud-based software that simplifies, digitizes, and automates financial operations for SMBs. Its artificial-intelligence enabled financial software platform used mostly to build connections between customers, suppliers, and clients. The company's platform generates and process invoices, streamline approvals, send and receive payments, sync with their accounting system, and manage their cash. The firm generates revenue through subscription and transaction fees.
Read more on BILL →
